Editas Medicine, Inc.

We are a pioneering gene editing company focused on developing genomic medicines to treat serious diseases. Our core capability uses CRISPR (clustered, regularly interspaced, short palindromic repeats) technology to create molecules that efficiently and specifically edit DNA. We have developed a proprietary gene editing platform based on CRISPR technology, which includes CRISPR/Cas9 and CRISPR/Cas12a systems, along with engineered forms and foundational intellectual property for both. This platform allows us to create gene editing molecules for over 95% of the human genome. Our mission is to translate gene editing into differentiated, transformational medicines for previously untreatable diseases. We aim to be a leader in in vivo gene editing, delivering therapies that simplify usability for patients, minimize burdens on patients and healthcare systems, and are distinct from current standards of care, while also enabling a simple, scalable manufacturing process to reduce costs.